Akari to Present Feb. 25 at Biocom Conference, Highlights AKTX-101 IND Progress
Akari Therapeutics will present at the 2026 Biocom Global Partnering & Investor Conference on February 25 at 11:00 AM PST in San Diego, offering one-on-one investor meetings. The oncology biotech is advancing its lead ADC candidate AKTX-101 into IND enabling studies with a first-in-human trial planned for late 2026.
1. Presentation Details
Akari Therapeutics will deliver an in-person presentation on Wednesday, February 25, 2026 at 11:00 AM PST in Track B of the Biocom Global Partnering & Investor Conference at The Lodge at Torrey Pines in San Diego. Management will be available for one-on-one meetings with registered investors during the conference window of February 24–26.
2. Lead ADC Candidate AKTX-101
AKTX-101 is Akari’s lead antibody drug conjugate targeting the Trop2 receptor with a proprietary PH1 spliceosome-modulating payload. Preclinical models show significant tumor cell killing and prolonged survival compared with traditional payload ADCs, and AKTX-101 has demonstrated synergy with checkpoint inhibitors.
3. IND Enabling and Trial Timeline
The company has initiated IND enabling studies for AKTX-101 and aims to start a first-in-human trial by late 2026 or early 2027. These studies will support regulatory filings and pave the way for clinical evaluation in solid tumors.
4. Second ADC Candidate AKTX-102
Akari’s second ADC program, AKTX-102, targets CEACAM5, a broadly expressed tumor antigen, using the same PH1 payload and novel antibody construct. This candidate is in early discovery and preclinical optimization to enable targeted tumor cell killing and immune activation.